Investors :: Carrick Therapeutics Limited

Latest News

View all news

Oct 18, 2023

Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer

Read more

Sep 7, 2023

Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13

Read more

Jul 6, 2023

Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination

Read more

View all news

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today

IR Contacts

Headquarters

Carrick Therapeutics Limited

T: +353 1 5996873
hello@carricktherapeutics.com